Impact of KIT mutation on efficacy of venetoclax and hypomethylating agents in newly diagnosed acute myeloid leukemia

Abstract Background The combination of venetoclax (VEN) with hypomethylating agents (HMAs) has emerged as a new standard treatment for older or unfit patients with acute myeloid leukemia (AML). However, the predictive factors for VEN/HMA efficacy remain unclear. In our study, we performed the first...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Wenxiu Shu, Qianqian Yang, Donghua He, Yi Li, Jing Le, Qianqian Cai, Hui Dai, Liufei Luo, Bingrong Chen, Yuan Gong, Dian Jin
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2025-05-01
coleção:	European Journal of Medical Research
Assuntos:	Acute myeloid leukemia KIT Venetoclax Hypomethylating agents Chemotherapy Prognosis
Acesso em linha:	https://doi.org/10.1186/s40001-025-02637-w
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!